$JSPR
Jasper Therapeutics, Inc. Stock $jspr

$jspr Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023066234 Filed on August 11, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.510M	$4.530M	$3.828M
YoY Change	22.35%	18.34%	17.35%
% of Gross Profit
Research & Development	$14.85M	$13.30M	$8.135M
YoY Change	64.58%	63.45%	57.78%
% of Gross Profit
Depreciation & Amortization	$300.0K	$275.0K	$218.0K
YoY Change	11.94%	26.15%	651.72%
% of Gross Profit
Operating Expenses	$19.36M	$17.83M	$11.96M
YoY Change	52.36%	49.02%	42.11%
Operating Profit	-$19.36M	-$17.83M	-$11.96M
YoY Change	52.36%	49.02%	42.11%
Interest Expense	$1.430M	$1.436M	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	$390.0K	$311.0K	$1.559M
YoY Change	-53.85%	-80.05%	-156000.0%
Pretax Income	-$17.54M	-$16.08M	-$10.40M
YoY Change	47.85%	54.56%	23.65%
Income Tax
% Of Pretax Income
Net Earnings	-$17.54M	-$16.08M	-$10.40M
YoY Change	47.89%	54.56%	23.65%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.16	-$0.15	-$0.29
Diluted Earnings Per Share	-$0.16	-$0.15	-$285.8K
COMMON SHARES
Basic Shares Outstanding	110.8M shares	110.3M shares	36.40M shares
Diluted Shares Outstanding	109.7M shares	109.2M shares	36.40M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$103.9M	$115.8M	$60.81M
YoY Change	103.93%	90.44%	262.92%
Cash & Equivalents	$103.9M	$115.8M	$60.81M
Short-Term Investments
Other Short-Term Assets	$1.100M	$653.0K	$27.00K
YoY Change	155.81%	2318.52%	-97.06%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$18.00K	$53.00K	$46.00K
Total Short-Term Assets	$105.2M	$118.6M	$63.29M
YoY Change	100.76%	87.35%	252.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.780M	$3.056M	$4.016M
YoY Change	-26.04%	-23.9%	-0.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$411.0K	$445.0K	$577.0K
YoY Change	-24.31%	-22.88%	-85.83%
Total Long-Term Assets	$5.187M	$5.603M	$7.080M
YoY Change	-22.57%	-20.86%	-12.79%
TOTAL ASSETS
Total Short-Term Assets	$105.2M	$118.6M	$63.29M
Total Long-Term Assets	$5.187M	$5.603M	$7.080M
Total Assets	$110.4M	$124.2M	$70.37M
YoY Change	86.78%	76.46%	169.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.256M	$1.581M	$2.997M
YoY Change	4.46%	-47.25%	-35.02%
Accrued Expenses	$8.200M	$7.002M	$3.106M
YoY Change	135.09%	125.43%	-31.39%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.91M	$8.972M	$6.622M
YoY Change	60.44%	35.49%	-27.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.297M	$2.314M	$749.0K
YoY Change	224.89%	208.95%	-77.23%
Total Long-Term Liabilities	$2.297M	$2.314M	$749.0K
YoY Change	224.89%	208.95%	-77.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.91M	$8.972M	$6.622M
Total Long-Term Liabilities	$2.297M	$2.314M	$749.0K
Total Liabilities	$16.27M	$13.97M	$11.59M
YoY Change	40.94%	20.54%	-6.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$153.0M	-$135.5M	-$80.06M
YoY Change	66.44%	69.21%
Common Stock	$11.00K	$11.00K	$4.000K
YoY Change	175.0%	175.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$94.13M	$110.2M	$58.78M
YoY Change
Total Liabilities & Shareholders Equity	$110.4M	$124.2M	$70.37M
YoY Change	86.78%	76.46%	169.69%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$17.54M	-$16.08M	-$10.40M
YoY Change	47.89%	54.56%	23.65%
Depreciation, Depletion And Amortization	$300.0K	$275.0K	$218.0K
YoY Change	11.94%	26.15%	651.72%
Cash From Operating Activities	-$11.98M	-$13.27M	-$9.356M
YoY Change	24.24%	41.86%	61.56%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$11.00K	-$243.0K
YoY Change	-100.0%	-104.53%	-15.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$11.00K	-$243.0K
YoY Change	-100.0%	-95.47%	-15.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	30.00K	-305.0K	13.00K
YoY Change	2900.0%	-2446.15%	-102.17%
NET CHANGE
Cash From Operating Activities	-11.98M	-13.27M	-9.356M
Cash From Investing Activities	0.000	-11.00K	-243.0K
Cash From Financing Activities	30.00K	-305.0K	13.00K
Net Change In Cash	-11.95M	-13.59M	-9.586M
YoY Change	21.15%	41.75%	43.55%
FREE CASH FLOW
Cash From Operating Activities	-$11.98M	-$13.27M	-$9.356M
Capital Expenditures	$0.00	$11.00K	-$243.0K
Free Cash Flow	-$11.98M	-$13.28M	-$9.113M
YoY Change	27.16%	45.76%	65.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39138
	dei	Entity Registrant Name EntityRegistrantName	JASPER THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-2984849
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2200 Bridge Pkwy
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite #102
	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94065
	dei	City Area Code CityAreaCode	(650)
	dei	Local Phone Number LocalPhoneNumber	549-1400
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	110800413	shares
	us-gaap	Other Income OtherIncome	12130000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	115812000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38250000	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	663000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2755000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2818000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	118567000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	41731000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3056000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3568000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1685000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1886000	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	417000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	417000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	445000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	759000	usd
CY2023Q2	us-gaap	Assets Assets	124170000	usd
CY2022Q4	us-gaap	Assets Assets	48361000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1581000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1768000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	917000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	865000	usd
CY2023Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	6474000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4432000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8972000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7065000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2317000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2786000	usd
CY2022Q4	jspr	Common Stock Warrant Liability CommonStockWarrantLiability	150000	usd
CY2023Q2	jspr	Earnout Liability EarnoutLiability	362000	usd
CY2022Q4	jspr	Earnout Liability EarnoutLiability	18000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2314000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2353000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	13965000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	12372000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	492000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	492000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110800413	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110800413	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38045677	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38045677	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	11000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	245669000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	141120000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-135475000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105135000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	110205000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	35989000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	124170000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48361000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13297000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8135000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23102000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16323000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4530000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3828000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8672000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8418000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	17827000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	11963000	usd
	us-gaap	Operating Expenses OperatingExpenses	31774000	usd
	us-gaap	Operating Expenses OperatingExpenses	24741000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17827000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11963000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-31774000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24741000	usd
CY2023Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	1436000	usd
CY2022Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	92000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	2532000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	94000	usd
CY2023Q2	jspr	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	-420000	usd
CY2022Q2	jspr	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	-625000	usd
	jspr	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	344000	usd
	jspr	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	-5218000	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-845000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	575000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6895000	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-109000	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-3000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-179000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-77000	usd
CY2023Q2	us-gaap	Other Income OtherIncome	1747000	usd
CY2022Q2	us-gaap	Other Income OtherIncome	1559000	usd
	us-gaap	Other Income OtherIncome	1434000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-16080000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-10404000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-30340000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12611000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109213669	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36397822	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98605265	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36353509	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	35989000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	32000	usd
CY2023Q1	jspr	Issuanceofcommonstockthroughunderwrittenofferingnetofdiscountsandcommissionsandissuancecosts Issuanceofcommonstockthroughunderwrittenofferingnetofdiscountsandcommissionsandissuancecosts	6600	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	96930000	usd
CY2023Q1	jspr	Issuance Of Common Stock Through Atm Offering Net Of Commissions And Offering Cost IssuanceOfCommonStockThroughATMOfferingNetOfCommissionsAndOfferingCost	100	usd
CY2023Q1	jspr	Issuance Of Common Stock Through Atm Offering Net Of Commissions And Offering Costs Of01 M IssuanceOfCommonStockThroughATMOfferingNetOfCommissionsAndOfferingCostsOf01M	4509000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	725000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	6000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1267000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-14260000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	125198000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	320000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	36000	usd
CY2023Q2	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-661000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1391000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-16080000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	110205000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	69518000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	3000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	778000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2207000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	68105000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	2000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1065000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-10404000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	58781000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-30340000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12611000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	549000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	434000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	201000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	151000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2658000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1843000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	575000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6895000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-344000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	5218000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-63000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-658000	usd
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-663000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-314000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-68000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-187000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-977000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2002000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-911000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-417000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-222000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-32000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	111000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23607000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23569000	usd
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	37000	usd
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	272000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-272000	usd
	jspr	Proceeds From Issuance Of Common Stock Through Atm And Underwriting Offerings Net ProceedsFromIssuanceOfCommonStockThroughATMAndUnderwritingOfferingsNet	101479000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	36000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	661000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	352000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	101206000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	77562000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-23815000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38667000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85046000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	116229000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61231000	usd
	jspr	Reclassification Of Common Stock Warrant Liability To Equity ReclassificationOfCommonStockWarrantLiabilityToEquity	725000	usd
	jspr	Unpaid Offerings Issuance Costs Included In Accounts Payable And Accrued Expenses UnpaidOfferingsIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses	40000	usd
	jspr	Vesting Of Founders Restricted Stock VestingOfFoundersRestrictedStock	7000	usd
	jspr	Vesting Of Founders Restricted Stock VestingOfFoundersRestrictedStock	5000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1074000	usd
	jspr	Accounts Payable And Accrued Expenses For Purchases Of Property And Equipment AccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment	211000	usd
	jspr	Noncash Leasehold Improvements NoncashLeaseholdImprovements	281000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Description of Business</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Jasper Therapeutics, Inc. and its consolidated subsidiary (collectively, “Jasper” or the “Company”), is a clinical-stage biotechnology company dedicated to enabling cures through therapeutics targeting mast and hematopoietic stem cells. The Company is focused on the development and commercialization of safer and more effective therapeutic agents for diseases such as Chronic Spontaneous Urticaria, Lower to Intermediate Risk Myelodysplastic Syndrome and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The Company is headquartered in Redwood City, California.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 24, 2021 (the “Closing Date”), the Company consummated the previously announced business combination (the “Business Combination” or “Reverse Recapitalization” for accounting purposes) pursuant to the terms of the Business Combination Agreement, dated as of May 5, 2021 (the “BCA”), by and among Amplitude Healthcare Acquisition Corporation (“AMHC”), Ample Merger Sub, Inc., a then-wholly-owned subsidiary of AMHC (“Merger Sub”), and the pre-Business Combination Jasper Therapeutics, Inc. (now named Jasper Tx Corp.) (“Old Jasper”). Pursuant to the terms of the BCA, on the Closing Date, (i) Merger Sub merged with and into Old Jasper, with Old Jasper as the surviving company in the Business Combination, and, after giving effect to such Business Combination, Old Jasper became a wholly owned subsidiary of AMHC and changed its name to “Jasper Tx Corp.”, and (ii) AMHC changed its name to “Jasper Therapeutics, Inc.”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Liquidity and Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company has incurred significant losses and negative cash flows from operations since its inception. During the three and six months ended June 30, 2023, the Company incurred net losses of $16.1 million and $30.3 million, respectively. During the three and six months ended June 30, 2022, the Company incurred net losses of $10.4 million and $12.6 million, respectively. During each of the six months ended June 30, 2023 and 2022, the Company had negative operating cash flows of $23.6 million. As of June 30, 2023 and December 31, 2022, the Company had an accumulated deficit of $135.5 million and $105.1 million, respectively. The Company expects to continue to incur substantial losses, and its ability to achieve and sustain profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenues to support the Company’s cost structure.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of June 30, 2023, the Company had cash and cash equivalents of $115.8 million. The Company’s management expects that the existing cash and cash equivalents will be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. The Company will need to raise additional financing to continue its products’ development for the foreseeable future, and expects to continue doing so until it becomes profitable. The Company’s management plans to monitor expenses and raise additional capital through a combination of public and private equity, debt financings, strategic alliances, and licensing arrangements. The Company’s ability to access capital when needed is not assured and, if capital is not available to the Company when, and in the amounts needed, the Company may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the commercialization of any product candidate, or be unable to expand its operations or otherwise capitalize on the Company’s business opportunities, as desired, which could materially harm the Company’s business, financial condition and results of operations.</p>
CY2023Q2	us-gaap	Profit Loss ProfitLoss	16100000	usd
	us-gaap	Profit Loss ProfitLoss	30300000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	10400000	usd
	us-gaap	Profit Loss ProfitLoss	12600000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	23600000	usd
CY2023Q2	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts	135500000	usd
CY2022Q4	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts	105100000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	115800000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgements that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the determination of the accrued research and development expenses, valuation of earnout liability and the measurement of stock-based compensation expense. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</p>
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	115812000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	38250000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	417000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	417000	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	116229000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	38667000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	1000000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3200000	usd
CY2023Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	114812000	usd
CY2023Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	114812000	usd
CY2023Q2	us-gaap	Other Liabilities OtherLiabilities	362000	usd
CY2023Q2	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	362000	usd
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	37250000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	37250000	usd
CY2022Q4	jspr	Common Stock Warrant Liability CommonStockWarrantLiability	150000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	18000	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	168000	usd
CY2023Q2	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	362	usd
	jspr	Valuation Methodology ValuationMethodology	Monte Carlo Simulation
	jspr	Common Stock Price CommonStockPrice	1.37
	jspr	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm	P1Y2M26D
	jspr	Expected Volatility ExpectedVolatility	1.39	pure
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3056000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3568000	usd
	jspr	Riskfree Interest Rate RiskfreeInterestRate	0.0514	pure
CY2022Q4	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	18	usd
CY2022	jspr	Valuation Methodology ValuationMethodology	Monte Carlo Simulation
CY2022	jspr	Common Stock Price CommonStockPrice	0.48
CY2022	jspr	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm	P1Y8M23D
CY2022	jspr	Expected Volatility ExpectedVolatility	1.05	pure
CY2022	jspr	Riskfree Interest Rate RiskfreeInterestRate	0.044	pure
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1168000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	842000	usd
CY2023Q2	us-gaap	Prepaid Insurance PrepaidInsurance	604000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1362000	usd
CY2023Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	277000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	250000	usd
CY2023Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	53000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	118000	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	653000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	246000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2755000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2818000	usd
CY2023Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2477000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2477000	usd
CY2023Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1743000	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1706000	usd
CY2023Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	502000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	502000	usd
CY2023Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	145000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	145000	usd
CY2023Q2	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	90000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	90000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4957000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4920000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1901000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1352000	usd
CY2022Q2	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	200000	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	500000	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	400000	usd
CY2023Q2	jspr	Research And Development Accrued Expenses ResearchAndDevelopmentAccruedExpenses	5157000	usd
CY2022Q4	jspr	Research And Development Accrued Expenses ResearchAndDevelopmentAccruedExpenses	2651000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	928000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1587000	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	389000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	194000	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	6474000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4432000	usd
CY2023Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2264000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2264000	usd
CY2023Q2	jspr	Restricted Stock Liabilities RestrictedStockLiabilities	2000	usd
CY2022Q4	jspr	Restricted Stock Liabilities RestrictedStockLiabilities	9000	usd
CY2023Q2	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	48000	usd
CY2022Q4	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	80000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2314000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2353000	usd
CY2020Q4	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	2300000	usd
	jspr	Percentage Of Licensing Fees PercentageOfLicensingFees	0.001	pure
	jspr	Fund Technology FundTechnology	1000000	usd
	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.60	pure
CY2023Q2	us-gaap	Investment Interest Rate InvestmentInterestRate	0.25	pure
	jspr	Received Aggregate From Cirm ReceivedAggregateFromCIRM	2300000	usd
CY2023Q2	us-gaap	Cash Cash	700000	usd
CY2023Q2	jspr	Other Receivables Milestone OtherReceivablesMilestone	50000	usd
	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	9000000	usd
	jspr	License Maintenance Fee LicenseMaintenanceFee	25000	usd
	us-gaap	Derivative Maturity Dates DerivativeMaturityDates	2026-09-24
CY2023Q2	jspr	Shares Of Nonvoting Common Stock SharesOfNonvotingCommonStock	911022	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4999863	shares
	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	700000	usd
CY2023Q2	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	0	usd
	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	600000	usd
CY2022Q2	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	800000	usd
	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	6900000	usd
CY2022Q4	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	200000	usd
	jspr	Contingent Earnout Liabilities Description ContingentEarnoutLiabilitiesDescription	Upon the closing of the Business Combination and pursuant to the Sponsor Support Agreement, the Sponsor agreed to place the Earnout Shares into escrow, which will be released as follows: (a) 250,000 Earnout Shares will be released if, during the period from and after September 24, 2021 until September 24, 2024 (the “Earnout Period”), over any twenty trading days within any thirty day consecutive trading day period, the volume-weighted average price of the Company’s common stock (the “Applicable VWAP”) is greater than or equal to $11.50, (b) 500,000 Earnout Shares will be released if, during the Earnout Period, the Applicable VWAP is greater than or equal to $15.00, and (c) 300,000 Earnout Shares will be released if, during the Earnout Period, the Applicable VWAP is greater than or equal to $18.00 (the “triggering events”).
CY2023Q2	jspr	Estimated Fair Value Of Earnout Liability EstimatedFairValueOfEarnoutLiability	400000	usd
CY2022Q4	jspr	Estimated Fair Value Of Earnout Liability EstimatedFairValueOfEarnoutLiability	100000	usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	400000	usd
	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	300000	usd
CY2020Q3	jspr	Rentable Square Feet With Lease Commencement RentableSquareFeetWithLeaseCommencement	7781	sqft
CY2022Q1	jspr	Rentable Square Feet With Lease Commencement RentableSquareFeetWithLeaseCommencement	5611	sqft
CY2022Q1	jspr	Agreement For Square Feet Of Temporary Office Space AgreementForSquareFeetOfTemporaryOfficeSpace	5144	sqft
	us-gaap	Payments For Rent PaymentsForRent	26000	usd
	jspr	Lessor Amount LessorAmount	400000	usd
CY2023Q2	us-gaap	Tenant Improvements TenantImprovements	1500000	usd
CY2023Q2	jspr	Additional Allowance AdditionalAllowance	400000	usd
CY2023Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.09	pure
CY2022Q4	jspr	Leasehold Improvement Gross LeaseholdImprovementGross	1900000	usd
CY2021Q4	jspr	Leasehold Improvement Gross LeaseholdImprovementGross	1900000	usd
	jspr	Net Construction Costs Percentage NetConstructionCostsPercentage	0.05	pure
	us-gaap	Operating Lease Cost OperatingLeaseCost	336000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	286000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	123000	usd
	us-gaap	Lease Cost LeaseCost	337000	usd
	us-gaap	Lease Cost LeaseCost	409000	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	553000	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	351000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M9D
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M13D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	566000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1153000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1187000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	740000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3646000	usd
CY2023Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Imputed Interest UnrecordedUnconditionalPurchaseObligationImputedInterest	412000	usd
CY2023Q2	jspr	Operating Lease Liabilites OperatingLeaseLiabilites	3234000	usd
CY2023Q2	jspr	Current Portion Of Lease Liability CurrentPortionOfLeaseLiability	-917000	usd
CY2023Q2	jspr	Noncurrent Portion Of Lease Liability NoncurrentPortionOfLeaseLiability	2317000	usd
	jspr	Pay Stanford Net PayStanfordNet	900000	usd
	jspr	Pay Stanford Net Term PayStanfordNetTerm	P3Y
	jspr	First Milestone Agremment FirstMilestoneAgremment	300000	usd
	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	300000	usd
	jspr	Third Mile Stone Amount ThirdMileStoneAmount	300000	usd
CY2022Q1	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	25000	usd
CY2023Q1	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	25000	usd
CY2023Q2	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	110800413	shares
CY2023Q2	jspr	Outstanding And Issued Common Stock Option OutstandingAndIssuedCommonStockOption	9345537	shares
CY2022Q4	jspr	Outstanding And Issued Common Stock Option OutstandingAndIssuedCommonStockOption	6169180	shares
CY2023Q2	jspr	Common Stock Warrant CommonStockWarrant	4999863	shares
CY2022Q4	jspr	Common Stock Warrant CommonStockWarrant	4999863	shares
CY2023Q2	us-gaap	Capital Units Outstanding CapitalUnitsOutstanding	1179771	shares
CY2022Q4	us-gaap	Capital Units Outstanding CapitalUnitsOutstanding	2617445	shares
CY2023Q2	jspr	Shares Available For Grant Under2021 Employee Stock Purchase Plan SharesAvailableForGrantUnder2021EmployeeStockPurchasePlan	1184572	shares
CY2022Q4	jspr	Shares Available For Grant Under2021 Employee Stock Purchase Plan SharesAvailableForGrantUnder2021EmployeeStockPurchasePlan	869117	shares
CY2023Q2	jspr	Shares Available For Grant Under2021 Equity Incentive Plan SharesAvailableForGrantUnder2021EquityIncentivePlan	855464	shares
CY2022Q4	jspr	Shares Available For Grant Under2021 Equity Incentive Plan SharesAvailableForGrantUnder2021EquityIncentivePlan	1383661	shares
CY2023Q2	jspr	Shares Available For Grant Under2019 Equity Incentive Plan SharesAvailableForGrantUnder2019EquityIncentivePlan	2301841	shares
CY2022Q4	jspr	Shares Available For Grant Under2019 Equity Incentive Plan SharesAvailableForGrantUnder2019EquityIncentivePlan	1295672	shares
CY2023Q2	jspr	Total Shares Of Common Stock Reserved TotalSharesOfCommonStockReserved	19867048	shares
CY2022Q4	jspr	Total Shares Of Common Stock Reserved TotalSharesOfCommonStockReserved	17334938	shares
	us-gaap	Proceeds From Sale Of Treasury Stock ProceedsFromSaleOfTreasuryStock	150000000	usd
	jspr	Common Stock CommonStock	250000000	usd
CY2023Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	69000000
CY2023Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	9000000	shares
CY2023Q1	jspr	Underwriting Agreement Price UnderwritingAgreementPrice	9000000
	jspr	Aggregate Offering Price AggregateOfferingPrice	15500000	usd
CY2023Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	2337496	shares
CY2023Q1	us-gaap	Demutualization By Insurance Entity Securities Issued Gross Cash Proceeds DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds	4500000	usd
CY2023Q2	jspr	Aggregate Offering Price AggregateOfferingPrice	75000000	usd
	jspr	Available Offering Amount AvailableOfferingAmount	175000000	usd
CY2023Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	75000000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	The number of shares available for issuance under the 2021 Plan will increase annually in an amount equal to the least of (i) 2,750,000 shares, (ii) a number of shares equal to 4% of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, or (iii) such lesser number of shares determined by the Company’s Board of Directors (“Board”) no later than the last day of the immediately preceding fiscal year. The number of shares of common stock available for issuance under the ESPP will increase annually in an amount equal to the least of (i) 550,000 shares of common stock, (ii) a number of shares of common stock equal to 1% of the total number of shares of all classes of common stock of the Company on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the Board. As of June 30, 2023, 6,453,566 shares were reserved for issuance under the 2021 Plan, of which 855,464 shares were available for future grant and 5,598,102 shares were subject to outstanding options and restricted stock units (“RSUs”), including performance-based awards. As of June 30, 2023, 124,435 shares have been issued under the ESPP and 1,184,572 shares were reserved and available for future issuance.
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2301841	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3198159	shares
CY2023Q2	jspr	Purchase Of Aggregate Shares PurchaseOfAggregateShares	555000	shares
	jspr	Fair Market Value Of Common Stock Percentage FairMarketValueOfCommonStockPercentage	0.85	pure
CY2023Q2	us-gaap	Reporting Unit Percentage Of Fair Value In Excess Of Carrying Amount ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount	1	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.10	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	400000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	100000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2100000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	800000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.44
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.91
	jspr	Stock Based Compensation For Unvested Options stockBasedCompensationForUnvestedOptions	10500000	usd
	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Period Remaining1 NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1	P3Y
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	100000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	463959	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.42
	jspr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P8Y21D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	50000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.92
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	16650	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.92
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	497309	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.45
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	202000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	497309	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.45
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y8M12D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	202000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	313959	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.78
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y11M15D
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	202000	usd
CY2023Q2	us-gaap	Unamortized Discounts On Acceptances Executed UnamortizedDiscountsOnAcceptancesExecuted	500000	usd
	us-gaap	Present Value Of Future Insurance Profits Weighted Average Amortization Period PresentValueOfFutureInsuranceProfitsWeightedAverageAmortizationPeriod	P0Y3M18D
CY2023Q2	us-gaap	Shares Issued SharesIssued	65001	shares
	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	100000	usd
CY2023Q2	jspr	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	100000	usd
CY2023Q2	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	900000	usd
CY2022Q2	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	480000	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	1699000	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	1036000	usd
CY2023Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	491000	usd
CY2022Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	585000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	959000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	807000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	1391000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	1065000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	2658000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	1843000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	100000	usd
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	100000	usd
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	100000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16080000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10404000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-30340000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-12611000	usd
CY2023Q2	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	110341633	shares
CY2022Q2	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	37886129	shares
	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	99775393	shares
	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	37877390	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	77964	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	438307	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	120128	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	473881	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1050000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1050000	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1050000	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1050000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109213669	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36397822	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98605265	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36353509	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2023Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	9345537	shares
CY2022Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	6023166	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	9345537	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	6023166	shares
CY2023Q2	jspr	Common Stock Warrants CommonStockWarrants	4999863	shares
CY2022Q2	jspr	Common Stock Warrants CommonStockWarrants	4999863	shares
	jspr	Common Stock Warrants CommonStockWarrants	4999863	shares
	jspr	Common Stock Warrants CommonStockWarrants	4999863	shares
CY2023Q2	jspr	Unvested Restricted Common Stock UnvestedRestrictedCommonStock	58829	shares
CY2022Q2	jspr	Unvested Restricted Common Stock UnvestedRestrictedCommonStock	400036	shares
	jspr	Unvested Restricted Common Stock UnvestedRestrictedCommonStock	58829	shares
	jspr	Unvested Restricted Common Stock UnvestedRestrictedCommonStock	400036	shares
CY2023Q2	jspr	Outstanding Rs Us OutstandingRSUs	1179771	shares
CY2022Q2	jspr	Outstanding Rs Us OutstandingRSUs	5000	shares
	jspr	Outstanding Rs Us OutstandingRSUs	1179771	shares
	jspr	Outstanding Rs Us OutstandingRSUs	5000	shares
CY2023Q2	jspr	Diluted Net Loss Per Share Attributable To Common Stockholders DilutedNetLossPerShareAttributableToCommonStockholders	15584000	shares
CY2022Q2	jspr	Diluted Net Loss Per Share Attributable To Common Stockholders DilutedNetLossPerShareAttributableToCommonStockholders	11428065	shares
	jspr	Diluted Net Loss Per Share Attributable To Common Stockholders DilutedNetLossPerShareAttributableToCommonStockholders	15584000	shares
	jspr	Diluted Net Loss Per Share Attributable To Common Stockholders DilutedNetLossPerShareAttributableToCommonStockholders	11428065	shares
CY2023Q2	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	100000	usd
CY2022Q2	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	100000	usd
	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	100000	usd
	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	300000	usd
CY2023Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense		usd
CY2023Q2	us-gaap	Restricted Stock Expense RestrictedStockExpense		usd
CY2022Q1	jspr	Issuance Of Common Stock Upon Exercise Of Common Stock Warrants IssuanceOfCommonStockUponExerciseOfCommonStockWarrants		usd
CY2022Q2	us-gaap	Restricted Stock Expense RestrictedStockExpense		usd
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets		usd
	jspr	Proceeds From Issuance Of Common Stock Through Atm And Underwriting Offerings Net ProceedsFromIssuanceOfCommonStockThroughATMAndUnderwritingOfferingsNet		usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans		usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation		usd
	jspr	Reclassification Of Common Stock Warrant Liability To Equity ReclassificationOfCommonStockWarrantLiabilityToEquity		usd
	jspr	Unpaid Offerings Issuance Costs Included In Accounts Payable And Accrued Expenses UnpaidOfferingsIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses		usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
	jspr	Accounts Payable And Accrued Expenses For Purchases Of Property And Equipment AccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment		usd
	jspr	Noncash Leasehold Improvements NoncashLeaseholdImprovements		usd
CY2023Q2	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109213669	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36353509	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36397822	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	98605265	shares
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001788028

Files In Submission

Name	View Source	Status
0001213900-23-066234-index-headers.html	Edgar Link	pending
0001213900-23-066234-index.html	Edgar Link	pending
0001213900-23-066234.txt	Edgar Link	pending
0001213900-23-066234-xbrl.zip	Edgar Link	pending
f10q0623ex10-2_jasperthera.htm	Edgar Link	pending
f10q0623ex31-1_jasperthera.htm	Edgar Link	pending
f10q0623ex31-2_jasperthera.htm	Edgar Link	pending
f10q0623ex32-1_jasperthera.htm	Edgar Link	pending
f10q0623_jasperthera.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
jspr-20230630.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
jspr-20230630_def.xml	Edgar Link	unprocessable
jspr-20230630_lab.xml	Edgar Link	unprocessable
jspr-20230630_pre.xml	Edgar Link	unprocessable
f10q0623_jasperthera_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
jspr-20230630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JSPR
Jasper Therapeutics, Inc. Stock $jspr

2023 Q3 Form 10-Q Financial Statement

#000121390023066234 Filed on August 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JSPR Jasper Therapeutics, Inc. Stock $jspr

2023 Q3 Form 10-Q Financial Statement

#000121390023066234 Filed on August 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JSPR
Jasper Therapeutics, Inc. Stock $jspr